Aukje K Mantel-Teeuwisse
Overview
Explore the profile of Aukje K Mantel-Teeuwisse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
180
Citations
1873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hogervorst M, Vreman R, Oduol T, Mantel-Teeuwisse A, Goettsch W, Kesselheim A
Clin Pharmacol Ther
. 2025 Mar;
PMID: 40059637
After a medicine has been tested in pivotal trials, regulators, health technology assessment (HTA) organizations, and professional societies make decisions about the patients best served by the medicine. This study...
2.
Vogler S, Zimmermann N, Knoll V, Salcher-Konrad M, Windisch F, Espin J, et al.
J Pharm Policy Pract
. 2025 Jan;
17(Suppl 1):2442002.
PMID: 39763616
On 25-26 April 2024, the 5th PPRI (Pharmaceutical Pricing and Reimbursement Information) Conference on ensuring equitable access to affordable medicines took place in Vienna (Austria). Twenty-four accepted contributions were presented...
3.
Jiu L, Wang J, Versteeg J, Zhang Y, Liu L, Somolinos-Simon F, et al.
Int J Technol Assess Health Care
. 2024 Nov;
40(1):e49.
PMID: 39498479
Objectives: A conceptual framework, called Innovation of Health Technology Assessment Methods (IHTAM), has been developed to facilitate the understanding of how to innovate methods of health technology assessment (HTA). However,...
4.
Callenbach M, Vreman R, Leopold C, Mantel-Teeuwisse A, Goettsch W
Pharmacoeconomics
. 2024 Oct;
43(1):53-66.
PMID: 39368017
Objective: To construct a framework and calculation tool to compare the consequences of implementing different payment models for high-cost, one-off potentially curative therapies and enable decision making to ultimately enhance...
5.
Ogar C, Gilbert H, Bloem L, Leopold C, Bassi P, Katagum Y, et al.
Vaccine
. 2024 Aug;
42(23):126196.
PMID: 39178765
Background: Adverse events following immunization (AEFIs), especially if serious, may impact vaccine recipients' quality of life and financial well-being and fuel vaccine hesitancy. Nigeria rolled out COVID-19 vaccination in 2021...
6.
Postma D, Heijkoop M, De Smet P, Notenboom K, Leufkens H, Mantel-Teeuwisse A
J Med Internet Res
. 2024 Aug;
26:e51317.
PMID: 39106483
Background: Early identification is critical for mitigating the impact of medicine shortages on patients. The internet, specifically social media, is an emerging source of health data. Objective: This study aimed...
7.
Joosse I, van den Ham H, Mantel-Teeuwisse A, Perumal-Pillay V, Suleman F
J Pharm Policy Pract
. 2024 Jul;
17(1):2372033.
PMID: 39011354
Background: We sought to identify what barriers and facilitators determine current perceived access to childhood cancer care in South Africa through in-depth interviews with stakeholders in South Africa's public and...
8.
Spin E, Mantel-Teeuwisse A, Pasmooij A
Front Med (Lausanne)
. 2024 Jun;
11:1387517.
PMID: 38882661
Introduction: Although drug repurposing holds great potential in addressing unmet needs, successful practical implementation is challenging and has been less widespread than anticipated. Regulators may play a critical role in...
9.
Callenbach M, Goettsch W, Mantel-Teeuwisse A, Trusheim M
Drug Discov Today
. 2024 Jun;
29(7):104048.
PMID: 38830504
Outcome-based reimbursement models are gaining attention for managing the clinical uncertainties and financial impact of gene and cell therapies. Little guidance exists on how such models can create win-win-win situations,...
10.
Hogervorst M, van Hattem C, Sonke G, Mantel-Teeuwisse A, Goettsch W, Bloem L
Drug Discov Today
. 2024 May;
29(7):104031.
PMID: 38796096
The tumour-agnostic authorisations of larotrectinib and entrectinib shifted the paradigm for indication setting. European healthcare decision-makers agreed on their therapeutic potential but diverged primarily in identified uncertainties concerning basket trial...